Close Menu

NEW YORK (GenomeWeb) – Rosetta Genomics today announced a deal to sell tests from Admera Health to oncologists and pathologists.

South Plainfield, NJ-based Admera is a molecular diagnostics spinoff of the clinical services unit of genomics contract research organization GeneWiz. As part of the deal, Rosetta will market Admera's tests, including PGxOne, which predicts how patients will respond to drugs based on their genetic profiles. Rosetta also will make available Admera's EGFR and KRAS clinical sequencing service.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

At the Lancet, more than two dozen public health researchers condemn the conspiracy theories that have emerged surrounding the source of the COVID-19 outbreak.

The Washington Post reports that Philip Leder, who helped uncover how DNA codes for proteins and studied the role of genes in cancer, has died.

Researchers from Trinity College Dublin and the University of Pittsburgh look into how often de novo genes arise and how important they may be.

In Nucleic Acids Research this week: pipeline for genotyping Alu retrotransposon mobile element insertions, previously undocumented non-coding RNAs, and more.

Mar
18
Sponsored by
Roche

This webinar will discuss data from a recent real-world comparison study evaluating performance of two cell-free DNA methodologies as first-line prenatal screens.

Mar
31
Sponsored by
Isoplexis

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.